Shots:

• Zydus has commenced the adaptive P-I/II human clinical trials of its plasmid DNA vaccine- ZyCoV-D and reported its first human dosing
• The Adaptive P-I/II dose escalation study will assess the safety- tolerability- and immunogenicity of the vaccine in ~1000 candidates across multiple clinical sites in India. The company has already manufacture clinical GMP batches of the vaccine candidate for the clinical trials
• ZyCoV-D has demonstrated a strong immune response and a high level of neutralizing Abs in its preclinical studies

  Ref: Zydus | Image: The Quint

Related News: Zydus to Initiate Clinical Trials Evaluating ZyCoV-D Vaccine Against COVID-19 in July 2020